SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6:303.
  • 2
    Sampaio EP, Kaplan G, Miranda A, Nery JAC, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168:40814.
  • 3
    Editorial. Thalidomide in dermatology and leprosy. Lancet 1985; 2:8081.
  • 4
    Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes OJ. Treatment of refractory rheumatoid arthritis—the thalidomide experience. J Rheumatol 1989; 16:15863.
  • 5
    Vogelsang GB, Farmer ER, Hess AD et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Eng J Med 1992; 326:10558.
  • 6
    Vogelsang GB, Hess AD, Gordon G, Brundrette R. Thalidomide induction of bone marrow transplantation tolerance. Transplantation Proc 1987; 19:2658.
  • 7
    Makonkawketoon S, Limson-Pobre RNR, Moreiera AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type I. Proc Natl Acad Sci USA 1993; 90:59748.
  • 8
    Keenan RJ, Eiras G, Burckart GJ et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. Transplantation 1991; 52:90810.
  • 9
    Coulson AS, Summers LJ, Lindahl-Kiessling K, Tucker D, Hellmann K. The effect of two soluble thalidomide derivatives on lymphocyte stimulation. Clin Exp Immunol 1970; 7:2417.
  • 10
    Barnhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984; 11:8149.
  • 11
    Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173:699703.
  • 12
    Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degredation. J Exp Med 1993; 177:167580.
  • 13
    Neubert R, Nogueira AC, Neubert D. Thalidomide and the immune system 2, Changes in receptors on blood cells of a healthy volunteer. Life Science 1992; 51:210716.
  • 14
    Hatfill SJ, Fester ED, de Beer DP, Bohm L. Introduction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites, Leukemia Research 1991; 15:12936.
  • 15
    Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7:14573.
  • 16
    Wierenga EA, Snoek M, de Groot C, Chretien I, Bos JD, Jansen HM, Kapsenberg ML. Evidence for compartmentalization of functional subsets of CD4+ T lymphocytes in atopic patients. J Immunol 1990; 144:46516.
  • 17
    Mosmann TR, Moore KW. The role of IL-10 in cross-regulation of Th1 and Th2 responses. Immunol Today 1991; 12:A49A53.
  • 18
    Powrie F, Coffman RL. Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol Today 1993; 14:2704.
  • 19
    McHugh SM, Wilson AB, Deighton J, Lachmann PJ, Ewan PW. IL-2, IL-6 and IFN-γ profiles from peripheral blood mononuclear cells of house dust mite allergic patients: a role for IL-6 in allergic disease. Eur J Allergy Clin Immunol 1994; 49:7519.
  • 20
    Wilson AB, McHugh SM, Deighton J, Ewan PW, Lachmann PJ. A competitive inhibition ELISA for the quantification of human interferon-γ. J Immunol Methods 1993; 162:24755.
  • 21
    Gillis S, Ferm W, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative micro assay for activity. J Immunol 1978; 120:202733.
  • 22
    Rolink AG, Melchers F, Palacios R. Monoclonal antibodies reactive with the mouse interleukin-5 receptor. J Exp Med 1989; 169:1693701.
  • 23
    Chen TL, Vogelsang GB, Petty BG, Brundrett RB, Noe DA, Santos GW, Colvin OM. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 1989; 17:4025.
  • 24
    Sigal NH, Lin CS, Siekierka JJ. Inhibition of human T cell activation by FK-506, rapamycin, and cyclosporine A. Transplant Proc 1991; 23:15.
  • 25
    Van Joost T, Stolz E, Heule F. Efficacy of low-dose cyclosporin in severe atopic skin disease. Arch Dermatol 1987; 123:1667.
  • 26
    Maggi E, Parronchi P, Manetti R et al. Recipricol regulatory effects of IFN-γ and IL-4 on the in vitro development of Th1 and Th2 clones. J Immunol 1992; 148:212447.
  • 27
    Del Pret GF, de Carli M, Mastromauro C et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 helper or type 2 helper) profile of cytokine production. J Clin Invest 1991; 88:34650.
  • 28
    Kabelitz D, Pohl T, Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 1993; 14:3389.
  • 29
    Murphy DB. T cell mediated immunosuppression. Curr Opin Immunol 1993; 5:4117.
  • 30
    Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 1993; 23:174551.
  • 31
    Pereira GMB, Miller JF, Shevach EM. Mechanism of action of cyclosporine A in vivo. T cell priming in vivo to alloantigen can be mediated by an IL-2-independent cyctosporine A-resistant pathway. J Immunol 1990; 144:210916.
  • 32
    Dearman RJ, Ramdin LSP, Basketter DA, Kimber I. Inducible interleukin-4-secreting cells provoked in mice during chemical sensitisation. Immunology 1991; 81:5517.
  • 33
    De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174;120920.
  • 34
    Clerici M, Shearer GM. A Th1 to Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14:10711.